Proactive Investors - Run By Investors For Investors

Alliance Pharma PLC well placed for future opportunities, says chief

John Dawson, chief executive of Alliance Pharma PLC (LON:APH), tells Proactive Investors that the recent acquisition of the Sinclair Healthcare Products Business has had a “transformational” effect on the business.

He says the deal doubles Alliance’s sales, profits, and market capitalisation, adding that the company is now “in a place that we can bid for other opportunities in the future”.

Dawson goes on to say it also gives the company a “much stronger presence across the top five EU countries,” as well as in China and South East Asia.

Alliance reported robust final statement for the year ended 31 December 2015 on Thursday, with revenue up 11% to £48.3mln, compared to £43.5mln the previous year. 

View full APH profile View Profile

Alliance Pharma PLC Timeline

January 21 2019
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use